CymaBay Therapeutics Inc. (CBAY) Covered Calls
You can sell covered calls on CymaBay Therapeutics Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for CBAY (prices last updated Mon 4:16 PM ET):
CymaBay Therapeutics Inc. (CBAY) Stock Quote | ||||||
---|---|---|---|---|---|---|
Last | Change | Bid | Ask | Volume | P/E | Market Cap |
32.46 | +0.01 | 32.47 | 32.48 | 3.3M | - | 3.7 |
Covered Calls For CymaBay Therapeutics Inc. (CBAY) | ||||||
---|---|---|---|---|---|---|
Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
Apr 19 | 32 | 0.45 | 32.03 | -0.1% | -1.1% | |
May 17 | 32 | 0.45 | 32.03 | -0.1% | -0.6% | |
Subscribers get access to the full covered call chain, and more features. |
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops arhalofenate, which has completed five Phase II clinical trials for the treatment of patients with gout; and MBX-2982, an oral G-protein coupled receptor agonist that has completed one Phase II clinical trial for therapeutic indications. It has licensing agreement with Kowa Pharmaceuticals America, Inc. for the development and commercialization of arhalofenate in the United States; and Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders, as well as a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Top 10 Open Interest For Apr 19 Expiration | Top 5 High Yield | |||||
---|---|---|---|---|---|---|
1. | IWM covered calls | 6. | TLT covered calls | 1. | SOUN covered calls | |
2. | SPY covered calls | 7. | QQQ covered calls | 2. | MRNS covered calls | |
3. | HYG covered calls | 8. | EEM covered calls | 3. | NOVA covered calls | |
4. | FXI covered calls | 9. | AAPL covered calls | 4. | DLO covered calls | |
5. | SLV covered calls | 10. | TSLA covered calls | 5. | CLSK covered calls |
Want more examples? CBAT Covered Calls | CBD Covered Calls